TL;DR: The Centers for Medicare & Medicaid Services modified NCD 334 governing outpatient intravenous insulin therapy (OIVIT), with an effective date of January 9, 2026. The position hasn't changed — OIVIT remains nationally non-covered under Medicare — but the formal policy update matters for billing teams who still see these claims come through.
CMS OIVIT coverage policy under NCD 334 Medicare confirms what it has said since December 23, 2009: no indication exists under which outpatient IV insulin therapy qualifies as reasonable and necessary. The policy does not list specific CPT or HCPCS codes, which creates its own billing problem. If your practice or facility bills for any services tied to an OIVIT regimen, expect denial — and if you're not sure where your claims fall, read through to section four before the January 9, 2026 effective date catches you off guard.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Outpatient Intravenous Insulin Treatment — NCD 334 |
| Policy Code | NCD 334 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium — low claim volume but high denial risk per claim |
| Specialties Affected | Endocrinology, Internal Medicine, Diabetes Management Clinics |
| Key Action | Audit any claims tied to OIVIT regimens and deny at charge capture — do not submit to Medicare |
CMS Outpatient IV Insulin Therapy Coverage Criteria and Medical Necessity Requirements 2026
The short answer on CMS outpatient IV insulin therapy coverage: there are none. No nationally covered indications exist under NCD 334.
CMS determined that OIVIT does not improve health outcomes in Medicare beneficiaries. That finding has driven the coverage policy since December 23, 2009. The January 9, 2026 update formalizes the current version of the policy — it does not expand or restrict what was already in place.
For medical necessity purposes, it does not matter how the regimen is described in the chart. OIVIT goes by many names — Cellular Activation Therapy (CAT), Chronic Intermittent Intravenous Insulin Therapy (CIIT), Hepatic Activation Therapy (HAT), Intercellular Activation Therapy (iCAT), Metabolic Activation Therapy (MAT), Pulsatile Intravenous Insulin Treatment (PIVIT), Pulse Insulin Therapy (PIT), and Pulsatile Therapy (PT). CMS covers none of them under any indication.
The medical necessity bar here is absolute. This is not a situation where documentation, a prior authorization, or a more specific ICD-10 code will change the outcome. If the service is part of an OIVIT regimen, the claim will be denied.
The policy applies to any service furnished "pursuant to an OIVIT regimen" as described in Section A of NCD 334. That definition is broad: pulsatile or continuous IV insulin infusion guided by respiratory quotient, urine urea nitrogen, glucose, or potassium measurements, performed in scheduled recurring periodic intermittent episodes. If a service fits that description, coverage is off the table.
CMS OIVIT Exclusions and Non-Covered Indications
Everything about OIVIT is non-covered. That's the entire substance of this policy.
CMS does carve out one important exception: individual components of an OIVIT regimen may have legitimate uses in conventional diabetes treatment. Blood glucose monitoring, infusion pumps, and glucose testing each have separate coverage pathways under Medicare. Those components are not blocked by NCD 334 — only when they are furnished as part of an OIVIT regimen does the non-coverage determination apply.
This distinction matters for billing. A patient receiving conventional IV insulin during a hospital stay, or using a home glucose monitor covered under NCD 40.2, is not subject to NCD 334. The policy targets the regimen, not the individual service codes.
The relevant cross-references in the NCD Manual are worth knowing:
| # | Excluded Procedure |
|---|---|
| 1 | Section 40.2 — Home Blood Glucose Monitors |
| 2 | Section 40.3 — Closed-loop Blood Glucose Control Devices (CBGCD) |
| 3 | Section 190.20 — Blood Glucose Testing |
| 4 | Section 280.14 — Infusion Pumps |
| 5 | Chapter 18, Section 90 — Diabetics Screening (Claims Processing Manual) |
If a patient's claim involves any of these services outside of an OIVIT regimen, those services are not automatically denied by NCD 334. Document carefully that the service is not part of an OIVIT regimen when billing for conventional diabetes care.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| OIVIT for any indication | Not Covered | No specific codes listed in NCD 334 | Nationally non-covered under all alternative names (CAT, CIIT, HAT, iCAT, MAT, PIVIT, PIT, PT) for dates of service on and after December 23, 2009 |
| Individual OIVIT components used in conventional diabetes treatment | Coverage determined separately | See NCD 40.2, 40.3, 190.20, 280.14 | Not governed by NCD 334 when furnished outside an OIVIT regimen |
| Blood glucose monitoring (conventional) | Covered per separate NCD | See NCD 40.2 | Not affected by NCD 334 |
| Infusion pumps (conventional use) | Covered per separate NCD | See NCD 280.14 | Not affected by NCD 334 |
CMS Outpatient IV Insulin Therapy Billing Guidelines and Action Items 2026
This policy is clear, but the billing risk is real — especially in practices that treat complex diabetes patients who may seek OIVIT through alternative medicine channels or wellness clinics.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture before January 9, 2026. Review any recurring outpatient IV insulin therapy claims in your billing queue. If those claims are tied to a pulsatile or continuous IV insulin regimen with scheduled periodic episodes, stop them before submission. Outpatient IV insulin therapy billing for Medicare under these conditions will result in claim denial. |
| 2 | Train your front desk and intake team on the alias names. Patients seeking OIVIT often come in with marketing language — "Cellular Activation Therapy," "Metabolic Activation Therapy," or "Pulse Insulin Therapy." Your team needs to recognize those terms and flag the encounter before it reaches the billing system. |
| 3 | Do not rely on prior authorization as a workaround. There is no prior authorization pathway for OIVIT under Medicare. This is a national coverage determination — no MAC can override it, and no prior auth approval from a plan will change NCD 334's effect on traditional Medicare claims. |
| 4 | Separate legitimate diabetes service claims from OIVIT regimen claims. If a patient receives conventional blood glucose monitoring or infusion pump services, those can still be billed under their respective NCDs. Document clearly in the chart that those services are not furnished as part of an OIVIT regimen. Without that documentation, you're exposed to a broader denial that sweeps up reimbursement for legitimate services. |
| 5 | Check your MAC's local coverage determinations for related services. NCD 334 is a national determination — it overrides any local coverage determination (LCD) from your Medicare Administrative Contractor on the specific question of OIVIT coverage. But for the peripheral components (glucose monitors, infusion pumps), your MAC's LCD guidance still applies. Know which MACs cover your geography and pull their LCDs for those specific items. |
| 6 | Flag any OIVIT-related claims for your compliance officer. If your billing team has been submitting claims for services that could be characterized as part of an OIVIT regimen, talk to your compliance officer before the January 9, 2026 effective date. This policy has been in place since 2009, and submitting claims that fall within the OIVIT definition creates Medicare fraud exposure — not just a denial. Get ahead of it. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Outpatient IV Insulin Therapy Under NCD 334
Covered CPT Codes
NCD 334 does not list any covered CPT or HCPCS codes. There are no nationally covered indications for OIVIT under Medicare.
Not Covered — Services Furnished as Part of an OIVIT Regimen
| Code | Type | Description | Reason |
|---|---|---|---|
| Not specified | — | Any service furnished pursuant to an OIVIT regimen | CMS has determined OIVIT is not reasonable and necessary for any indication under Section 1862(a)(1)(A) of the Social Security Act |
The policy does not list specific procedure codes because the non-coverage determination is regimen-based, not code-based. Any service — regardless of the code — that is furnished as part of an OIVIT regimen is non-covered. This is an important structural point: you cannot recode your way out of an OIVIT denial. If the service fits the regimen definition in Section A of NCD 334, the code doesn't matter.
Key ICD-10-CM Diagnosis Codes
NCD 334 does not list specific ICD-10-CM diagnosis codes. The non-coverage determination applies regardless of the underlying diagnosis used to justify the OIVIT regimen.
A Note on the Absence of Codes
The lack of specific codes in NCD 334 is not an oversight — it's the point. CMS wrote this determination to cover the regimen as a whole, not individual line items. That makes OIVIT billing risk harder to catch in your charge capture system, because there's no code-level flag to trigger a denial rule.
Your best defense is a pre-billing clinical review workflow. Any outpatient IV insulin claim should clear a simple question: is this service part of a recurring, scheduled OIVIT regimen? If yes, pull the claim. If no, document why not.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.